Proteomarine LLC develops biopharmaceutical drugs based on variable fragments of shark antibodies. The company’s pipeline includes drugs for hypercholesterolemia, cancer, and COVID-19.
The high specificity of these drugs minimizes side effects. The small size of shark antibodies increases their bioavailability in the body, allowing them to be used in the form of less invasive subcutaneous rather than intravenous injections.
The stability of shark antibodies makes them convenient for storage, transportation and suitable for intranasal drugs.
CVD, oncology
The biopharmaceutical drug binds to PD-L1 to activate the immune system to fight tumor cells.